Multiple Myeloma | Oncology Today with Dr Neil Love: Key Presentations from the 64th American Society of Hematology (ASH) Annual Meeting — Multiple Myeloma Edition
Research To Practice | Oncology Videos · Dr. Neil Love
April 19, 20231h 14m
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Featuring perspectives from Dr Jacob Laubach, including the following topics:
- Evolution of first-line treatment for multiple myeloma (MM) (0:00)
- Perspectives on the future of bispecific antibody and chimeric antigen receptor (CAR) T-cell therapy for the management of MM (13:27)
- ASH 2022 updates on front-line management of MM for transplant-ineligible patients (18:35)
- ASH 2022 updates on the use of isatuximab-containing regimens for newly diagnosed and relapsed/refractory (R/R) MM (24:57)
- ASH 2022 updates on the clinical efficacy of CAR T-cell therapy for R/R MM; perspectives on the future of belantamab mafodotin (35:05)
- ASH 2022 updates on the efficacy and safety of teclistamab for R/R MM (46:33)
- Bispecific antibody therapy administration and patient education (52:41)
- ASH 2022 updates on investigational bispecific antibodies and other novel therapies for MM (1:00:17)